

NOTICE: This is a translation of the notice issued on June 23, 2026 in Japanese and is provided for your convenience only. In case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536
June 23, 2026

**RESOLUTION NOTICE
OF THE 114TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
OF SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, at the 114th Annual General Meeting of Shareholders of the Company that was held today.

Very truly yours,

Takeshi Ito
Representative Director, President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
4-20, Ofuka-cho, Kita-ku, Osaka, Japan

Reports:

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 114th Business Term (April 1, 2025 to March 31, 2026)
2. Report on the Audit Reports of the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 114th Business Term (April 1, 2025 to March 31, 2026)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No. 1: Appropriation of Surplus

As to this item, the Year-end dividends were resolved to be JPY 19 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed, are at JPY 38 per share.

Proposal No. 2: Appointment of Seven (7) Directors

As regards this item, Takeshi Ito, Rie Nakajima, Ippei Kurihara, Masahiko Ikaga, Minoru Kikuoka, Yukiko Kuroda and Tetsuya Uekusa were appointed as Directors as per the original proposal; each of them assumed his or her office.

Masahiko Ikaga, Minoru Kikuoka, Yukiko Kuroda and Tetsuya Uekusa are Outside Directors.

ANNOUNCEMENT

At the meeting of the Board of Directors, which was held after the close of this Annual General Meeting of Shareholders, Takeshi Ito was appointed as Representative Director, President and CEO. He assumed the said office.

As a result thereof, the Directors and Corporate Auditors of the Company shall be as follows:

Directors and Corporate Auditors

Takeshi Ito	Representative Director, President and Chief Executive Officer
Rie Nakajima	Director, Corporate Officer, Chief Operating Officer
Ippei Kurihara	Director, Corporate Officer, Head of Japan Business, Business Development
Masahiko Ikaga*	Director
Minoru Kikuoka*	Director
Yukiko Kuroda*	Director
Tetsuya Uekusa*	Director
Hiroshi Isaka	Standing Corporate Auditor
Junichi Asatani**	Corporate Auditor
Yaeko Hodaka**	Corporate Auditor
Yuichiro Munakata**	Corporate Auditor

* The Outside Directors (indicated by an asterisk (*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.).

** The Outside Corporate Auditors (indicated by two asterisks (**)) next to their names) are Independent Officers.

End.